Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus.

The article discusses the use of neoadjuvant axitinib in treating renal cell carcinoma with venous tumor thrombus (VTT). The NAXIVA trial showed a 35% response rate to axitinib after 8 weeks of treatment. The study used various methods such as digital pathology, flow cytometry, and RNA sequencing to identify predictors of response, including plasma CCL17 and IL-12. These findings could potentially improve treatment strategies for VTT in the future. [Extracted from the article]